New combination of medicines shrinks tumors in most patients with an aggressive form of cancer

New combination of medicines shrinks tumors in most patients with an aggressive form of cancer

An experimental daily pill, used alongside standard chemotherapy, shrank tumors or kept them from growing in most people with advanced pancreatic cancer, according to early trial results presented at an international cancer meeting.

The phase 1/2 study, presented at the EORTC-NCI-AACR Symposium in Barcelona, tested daraxonrasib with two intravenous chemotherapy drugs: gemcitabine and nab-paclitaxel. It included 61 patients whose cancer had spread to other organs and who had not yet received treatment for their advanced disease.

Pancreatic cancer is often diagnosed after it has spread, making it especially difficult to treat. In earlier trials of chemotherapy for metastatic disease, tumors shrank in roughly 23% to 42% of patients. The cancer commonly began growing again within five to six months, and typical survival ranged from eight to 11 months. National Cancer Institute data show that about 3% of people with distant-stage disease survive five years after diagnosis.

After a median follow-up of 18 months, tumors had shrunk in 60.7% of the study participants. In 8.2% of cases, scans showed no visible tumor. Overall, the treatment combination stopped the cancer from growing in 90.2% of patients.

The median time before the cancer worsened was 12.8 months, nearly twice the period typically reported with chemotherapy alone. About 76.6% of participants were alive after one year. The study’s lead investigator, Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center, said the results included substantial tumor reductions and disease control lasting beyond a year for many patients.

More than 90% of pancreatic cancers are driven by changes in the RAS gene, which can send signals that help tumors grow. Daraxonrasib is designed to block that signal, a target that researchers had long considered difficult to address with medication.

Dr. Elena Garralda, chair of the symposium and co-director of the clinical research program at Spain’s Vall d’Hebron Institute of Oncology, said the findings suggest RAS-targeting drugs may be combined with existing treatments from the outset. She was not involved in the study.

Reported side effects included rash, diarrhea, fatigue and low blood cell counts associated with chemotherapy. Most could be managed with standard care, and 5% of patients stopped treatment because of side effects attributed to daraxonrasib.

The results need to be interpreted cautiously. This was a small, early-stage study, and everyone received the experimental combination. There was no group receiving chemotherapy alone for comparison, so researchers cannot yet say how much the combination improves outcomes or whether it extends overall survival.

The findings apply to metastatic pancreatic cancer. Although RAS changes are involved in several other cancers, including some lung, colorectal and gynecological cancers, separate trials would be needed to assess the treatment in those diseases.

Revolution Medicines, the California-based company developing daraxonrasib, funded the study. Researchers have begun a larger randomized phase 3 trial, RASolute-303, comparing daraxonrasib alone and daraxonrasib with chemotherapy against standard chemotherapy.

Facebook
Twitter
LinkedIn
Reddit
Telegram
WhatsApp

Related News